Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.43 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.33 |
| ▸ | POLA1 | P09884 | 1/20 | 0.32 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18880979 | 0.89 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL17099404 | 0.79 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL17807711 | 0.78 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL19245305 | 0.78 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL19245183 | 0.78 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL5144346 | 0.78 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL51723 | 0.78 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL18880982 | 0.77 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL27979205 | 0.77 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| Hydrochloric Acid SCHEMBL27782735 | 0.77 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180162896-A1 | Synthesis of Phosphoramidates | SANDOZ AG (CH) | 2018-06-14 | — | — | US | disclosed |
| EP-2794629-B1 | 2',4'-DIFLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | RIBOSCIENCE LLC (US) | 2017-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162896-A1 | Synthesis of Phosphoramidates | PNP, MTAP, SAMHD1 | SLC28A1 122/4885SLC28A2 179/4885SLC29A1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.